Atracurium: conception and inception.

Area of Science:

• Pharmacology
• Biochemistry
• Anesthesiology

Background:

• Neuromuscular blocking agents are crucial in anesthesia.
• Existing agents often rely on renal or hepatic clearance, limiting their use in patients with organ dysfunction.
• A novel biodegradation pathway is needed for safer neuromuscular blockade.

Purpose of the Study:

• To describe the rationale behind the design of atracurium.
• To highlight the Hofmann elimination pathway in atracurium's biodegradation.
• To explain how this design ensures predictable action and safe metabolism.

Main Methods:

• Detailed description of the chemical structure of atracurium.
• Explanation of the Hofmann elimination mechanism.
• Discussion of ester hydrolysis as a parallel degradation pathway.
• In vivo studies to confirm breakdown products and their effects.

Main Results:

• Atracurium is a bis-quaternary ammonium compound.
• Hofmann elimination provides a non-enzymatic biodegradation route.
• Ester hydrolysis contributes to the breakdown of atracurium.
• Degradation products are pharmacologically inert, with no neuromuscular or cardiovascular effects.
• The duration of action is independent of plasma esterase activity, renal, or hepatic function.

Conclusions:

• Atracurium's design offers a unique biodegradation pathway via Hofmann elimination.
• This pathway ensures predictable duration of action and safe metabolism.
• Atracurium provides a valuable option for neuromuscular blockade, especially in patients with compromised organ function.